Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
[en] The aim of our study was to determine the potential role of CT-based radiomics in predicting treatment response and survival in patients with advanced NSCLC treated with immune checkpoint inhibitors. We retrospectively included 188 patients with NSCLC treated with PD-1/PD-L1 inhibitors from two independent centers. Radiomics analysis was performed on pre-treatment contrast-enhanced CT. A delta-radiomics analysis was also conducted on a subset of 160 patients who underwent a follow-up contrast-enhanced CT after 2 to 4 treatment cycles. Linear and random forest (RF) models were tested to predict response at 6 months and overall survival. Models based on clinical parameters only and combined clinical and radiomics models were also tested and compared to the radiomics and delta-radiomics models. The RF delta-radiomics model showed the best performance for response prediction with an AUC of 0.8 (95% CI: 0.65−0.95) on the external test dataset. The Cox regression delta-radiomics model was the most accurate at predicting survival with a concordance index of 0.68 (95% CI: 0.56−0.80) (p = 0.02). The baseline CT radiomics signatures did not show any significant results for treatment response prediction or survival. In conclusion, our results demonstrated the ability of a CT-based delta-radiomics signature to identify early on patients with NSCLC who were more likely to benefit from immunotherapy.
Disciplines :
Radiology, nuclear medicine & imaging Cardiovascular & respiratory systems
Author, co-author :
Cousin, François ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco
Louis, Thomas ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco ; Radiomics (Oncoradiomics SA), 4000 Liège, Belgium
Dheur, Sophie ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de radiodiagnostic
Aboubakar, Frank ; Department of Pulmonology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 1200 Bruxelles, Belgium ; Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, 1200 Bruxelles, Belgium
Ghaye, Benoit; Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, 1200 Bruxelles, Belgium ; Department of Radiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 1200 Bruxelles, Belgium
Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Garon E.B. Hellmann M.D. Rizvi N.A. Carcereny E. Leighl N.B. Ahn M.J. Eder J.P. Balmanoukian A.S. Aggarwal C. Horn L. et al. Five-Year Overall Survival for Patients with Advanced Non-Small-Cell Lung Cancer Treated with Pembrolizumab: Results from the Phase I KEYNOTE-001 Study J. Clin. Oncol. 2019 37 2518 2527 10.1200/JCO.19.00934 31154919
Garon E.B. Rizvi N.A. Hui R. Leighl N. Balmanoukian A.S. Eder J.P. Patnik A. Aggarwal C. Gubens M. Horn L. et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer N. Engl. J. Med 2015 372 2018 2028 10.1056/NEJMoa1501824
Reck M. Rodríguez–Abreu D. Robinson A.G. Hui R. Csőszi T. Fülöp A. Gottfried M. Peled N. Tafreshi A. Cuffe S. et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater J. Clin. Oncol. 2019 37 537 546 10.1200/JCO.18.00149
Horn L. Spigel D.R. Vokes E.E. Holgado E. Ready N. Steins M. Poddubskaya E. Borghaei H. Felip E. Paz-Ares L. et al. Nivolumab Versus Docetaxel in Previously Treated Patients with Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes from Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) J. Clin. Oncol. 2017 35 3924 3933 10.1200/JCO.2017.74.3062
Herbst R.S. Baas P. Kim D.W. Felip E. Pérez-Gracia J.L. Han J.Y. Molina J. Kim J.-H. Arvis C.D. Ahn M.-J. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial Lancet 2016 387 1540 1550 10.1016/S0140-6736(15)01281-7
Planchard D. Popat S. Kerr K. Novello S. Smit E.F. Faivre-Finn C. Mok T.S. Reck M. Van Schil P.E. Hellmann M.D. et al. Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann. Oncol. 2018 29 192 237 10.1093/annonc/mdy275
Ilie M. Long-Mira E. Bence C. Butori C. Lassalle S. Bouhlel L. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: A potential issue for anti-PD-L1 therapeutic strategies Ann. Oncol. 2016 27 147 153 10.1093/annonc/mdv489 26483045
Büttner R. Gosney J.R. Skov B.G. Adam J. Motoi N. Bloom K.J. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer J. Clin. Oncol. 2017 35 3867 3876 10.1200/JCO.2017.74.7642 29053400
Hellmann M.D. Paz-Ares L. Bernabe Caro R. Zurawski B. Kim S.W. Carcereny Costa E. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer N. Engl. J. Med. 2019 381 2020 2031 10.1056/NEJMoa1910231
Gadgeel S. Rodríguez-Abreu D. Speranza G. Esteban E. Felip E. Dómine M. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer J. Clin. Oncol. 2020 38 1505 1517 10.1200/JCO.19.03136
Heeke S. Hofman P. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: Getting ready for prime-time or not Transl. Lung Cancer Res. 2018 7 631 638 10.21037/tlcr.2018.08.04
Frix A.N. Cousin F. Refaee T. Bottari F. Vaidyanathan A. Desir C. Radiomics in Lung Diseases Imaging: State-of-the-Art for Clinicians J. Pers. Med. 2021 11 602 10.3390/jpm11070602
Bidzińska J. Szurowska E. See Lung Cancer with an AI Cancers 2023 15 1321 10.3390/cancers15041321
Aerts H.J.W.L. Velazquez E.R. Leijenaar R.T.H. Parmar C. Grossmann P. Carvalho S. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach Nat. Commun. 2014 5 4006 10.1038/ncomms5006
Sun R. Limkin E.J. Vakalopoulou M. Dercle L. Champiat S. Han S.R. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: An imaging biomarker, retrospective multicohort study Lancet Oncol. 2018 19 1180 1191 10.1016/S1470-2045(18)30413-3
Yoon H.J. Kang J. Park H. Sohn I. Lee S.H. Lee H.Y. Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles PLoS ONE. 2020 15 e0231227 10.1371/journal.pone.0231227
Trebeschi S. Drago S.G. Birkbak N.J. Kurilova I. Cǎlin A.M. Pizzi A.D. Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers Ann. Oncol. 2019 30 998 1004 10.1093/annonc/mdz108
Tang C. Hobbs B. Amer A. Li X. Behrens C. Canales J.R. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer Sci. Rep. 2018 8 1922 10.1038/s41598-018-20471-5 29386574
Liu Y. Wu M. Zhang Y. Luo Y. He S. Wang Y. Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer Front. Oncol. 2021 11 657615 10.3389/fonc.2021.657615 33816314
Khorrami M. Prasanna P. Gupta A. Patil P. Velu P.D. Thawani R. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer Cancer Immunol. Res. 2020 8 108 119 10.1158/2326-6066.CIR-19-0476 31719058
Gong J. Bao X. Wang T. Liu J. Peng W. Shi J. A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer Oncoimmunology 2022 11 2028962 10.1080/2162402X.2022.2028962
Nardone V. Reginelli A. Grassi R. Boldrini L. Vacca G. D’Ippolito E. Delta radiomics: A systematic review Radiol. Med. 2021 126 1571 1583 10.1007/s11547-021-01436-7 34865190
Barabino E. Rossi G. Pamparino S. Fiannacca M. Caprioli S. Fedeli A. Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics Cancers 2022 14 350 10.3390/cancers14020350
Nardone V. Reginelli A. Guida C. Belfiore M.P. Biondi M. Mormile M. Delta-radiomics increases multicentre reproducibility: A phantom study Med. Oncol. Northwood Lond. Engl. 2020 37 38 10.1007/s12032-020-01359-9
Plautz T.E. Zheng C. Noid G. Li X.A. Time stability of delta-radiomics features and the impact on patient analysis in longitudinal CT images Med. Phys. 2019 46 1663 1676 10.1002/mp.13395 30695103
Chai L.F. Prince E. Pillarisetty V.G. Katz S.C. Challenges in assessing solid tumor responses to immunotherapy Cancer Gene Ther. 2020 27 528 538 10.1038/s41417-019-0155-1 31822814
Lambin P. Leijenaar R.T.H. Deist T.M. Peerlings J. de Jong E.E.C. Van Timmeren J. Radiomics: The bridge between medical imaging and personalized medicine Nat. Rev. Clin. Oncol. 2017 14 749 762 10.1038/nrclinonc.2017.141
Wu M. Zhang Y. Zhang J. Zhang Y. Wang Y. Chen F. A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study Front. Oncol. 2022 11 688679 10.3389/fonc.2021.688679
Xie D. Xu F. Zhu W. Pu C. Huang S. Lou K. Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy Front. Oncol. 2022 12 990608 10.3389/fonc.2022.990608
Paijens S.T. Vledder A. de Bruyn M. Nijman H.W. Tumor-infiltrating lymphocytes in the immunotherapy era Cell Mol. Immunol. 2021 18 842 859 10.1038/s41423-020-00565-9
Petitprez F. Meylan M. de Reyniès A. Sautès-Fridman C. Fridman W.H. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies Front. Immunol. 2020 11 784 10.3389/fimmu.2020.00784
Tumeh P.C. Harview C.L. Yearley J.H. Shintaku I.P. Taylor E.J.M. Robert L. PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 2014 515 568 571 10.1038/nature13954 25428505
Ligero M. Garcia-Ruiz A. Viaplana C. Villacampa G. Raciti M.V. Landa J. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors Radiology 2021 299 109 119 10.1148/radiol.2021200928
Yang Y. Yang J. Shen L. Chen J. Xia L. Ni B. A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer Am. J. Transl. Res. 2021 13 743 756 33594323
Yang F. Wang Y. Tang L. Mansfield A.S. Adjei A.A. Leventakos K. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis Front. Oncol. 2022 12 955440 10.3389/fonc.2022.955440 36052255
Brahmer J.R. Lee J.S. Ciuleanu T.E. Bernabe Caro R. Nishio M. Urban L. Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 J. Clin. Oncol. 2023 41 1200 1212 10.1200/JCO.22.01503 36223558